Body Systems

Hepatitis C9 Results found

Studies recruiting participants:

Gilead Sustained Virologic Response (SVR) Registry

This Registry is designed to provide long term clinical and virologic follow up in subjects who have achieved sustained virologic response (SVR) while participating in a previous Gilead sponsored Hepatitis C Virus (HCV) study.

Recruiting
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Hepatitis C
Area 
Vancouver
Age 
18 and above

Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With…

This three-year study (participants with chronic kidney disease [CKD] or cirrhosis will be followed for five years) multicenter study is being done to follow participants who received at least one dose of grazoprevir (MK-5172) in a previous study to determine if they remain hepatitis C virus (HCV

Recruiting
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Hepatitis C
Area 
Vancouver
Age 
18 and above

Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (SOF/VEL ESRD)

The primary objectives of this study are to evaluate safety, efficacy and tolerability of treatment with sofosbuvir (Sovaldi®)/velpatasvir (Epclusa®; SOF/VEL) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection who are on dialysis for End Stage Renal Disease (ESRD).

Recruiting
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Hepatitis C
Area 
Vancouver
Age 
18 years and above

Efficacy and Safety of MK-3682B (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral…

This is a randomized, multicenter, open-label trial of the combination regimen of MK-5172 (grazoprevir [GZR]) (100 mg), MK-3682 (450 mg) and MK-8408 (ruzasvir) (60 mg) for 16 weeks with ribavirin (RBV) or 24 weeks without RBV in cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) genotype

Recruiting
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Hepatitis C
Area 
Vancouver
Age 
18 and above

Closed for recruitment:

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (AMBER)

This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free ABBVIE REGIMEN ± RBV in participants with chronic hepatitis C (CHC) in a real life setting across clinical practice patient populations in Canada.
 

Closed for Recruitment
Principal Investigator 
Eric M. Yoshida
Body Locations and Systems 
Hepatitis C
Area 
Vancouver
Age 
18-99